Genome wide association study based on clustering by obesity-related variables shed

light on a genetic architecture of obesity in Japanese and UK population

Ippei Takahashi¹, Hisashi Ohseto¹, Fumihiko Ueno^{1,2}, Tomomi Onuma², Akira Narita^{1,2}, Taku Obara^{1,2,3}, Mami Ishikuro^{1,2}, Keiko Murakami^{1,2}, Aoi Noda^{1,2,3}, Atsushi Hozawa^{1,2}, Junichi Sugawara^{1,2}, Gen Tamiya^{1,2,4}, Shinichi Kuriyama^{1,2,5*}

¹Graduate School of Medicine, Tohoku University, Sendai, Japan.

²Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.

³Tohoku University Hospital, Sendai, Japan.

⁴RIKEN Center for Advanced Intelligence Project, Tokyo, Japan.

⁵International Research Institute of Disaster Science, Tohoku University, Sendai, Japan.

Financial Support

The Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study and the Community-Based Cohort Study were supported by the Japan Agency for Medical Research and Development (AMED) (grant numbers JP20km0105001 and JP21km0105002). This study was also supported by the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) KAKENHI (grant numbers 19H03894 and 22H03346). AMED and MEXT had no role in the design or execution of the study.

Conflict of Interest and Funding Disclosure

No conflicts of interest

Corresponding Author

Shinichi Kuriyama

Mailing address: Tohoku Medical Megabank Organization, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8573, Japan. E-mail address: kuriyama@med.tohoku.ac.jp

Telephone: +81 22-717-8104

Running title: Genetic architecture of Obesity

Abbreviations

AS: antisense RNA; BDNF: brain-derived neurotrophic factor; BirThree Cohort Study: Birth and Three-Generation Cohort Study, CommCohort Study; BMI: body mass index; cGWAS: cluster-based GWAS; FFQ: food frequency questionnaire; GRM: genetic relationship matrix; GWAS: genome-wide association study; HWE: Hardy-Weinberg equilibrium; KNN: knearest neighbors; MAF: minor allele frequency; MC4R: melanocortin-4-receptors; PCA: principal component analysis; SD: standard deviation; TMM: Tohoku Medical Megabank Project, Community-Based Cohort Study

1 Abstract

2	Background: Many loci associated with obesity have been reported in previous genome-
3	wide association studies (GWASs). However, it remains unclear whether variants at all these
4	loci contributed to onset of obesity or whether one or a few variants cause obesity when
5	obesity is a genetically heterogeneous population.
6	Objective: To investigate the genetic architecture of obesity by clustering a population with
7	obesity into clusters using obesity-related factors.
8	Methods: This study was based on the Tohoku Medical Megabank Project Birth and Three-
9	Generation Cohort Study and the Community-Based Cohort Study. As the Step-1, a GWAS
10	with body mass index (BMI) as an outcome was performed for all 48,365 eligible participants.
11	As the Step-2, we then assigned the 13,067/48,365 participants with obesity (BMI \ge 25
12	kg/m ²) using the k-prototype to 5 clusters. Obesity-related factors (such as age, nutrient
13	intake, physical activity, sleep duration, difference between weight at age 20 and current
14	weight, smoking, alcohol drinking, psychological distress, and birth weight) were used for
15	clustering. Subsequently, participants in each cluster and those with a $BMI < 25 \text{ kg/m}^2$ were
16	combined, and GWASs were performed according to the 5 clusters. Additionally, a sub-
17	analysis using data from the UK Biobank was conducted to compare the results.
18	Results: The Step-1 detected 18 genes, most of which were reportedly associated with
19	obesity or obesity-related topics in previous studies. The result of Step-2, of the 18 genes
20	detected in Step-1, LINC01741, CRYZL2P-SEC16B, and SEC16B were significantly related
21	to Cluster 2, FTO, PMAIP1, and MC4R to Cluster 3, and BDNF, BDNF-AS, LINC00678, and
22	KIF18A to Clusters 4 and 5. In the sub-analysis, a similar phenomenon was observed in
23	which separate obesity-related genes were detected for each cluster.
24	Conclusions: Our data support the notion that a decreased sample size with increased
25	homogeneity may reveal insights into the genetic architecture of obesity.

26 Keywords: GWAS, obesity, BMI, cGWAS, cluster analysis

27

28 Introduction

29	Obesity is a serious global medical and economic issue that represents a major risk factor for
30	many lifestyle-related diseases, such as diabetes, hyperlipidemia, and hypertension (1,2). The
31	global proportion of individuals with a body-mass index (BMI) $\geq 25 \text{ kg/m}^2$ is reportedly
32	36.9% for men and 38.0% for women (3). The pathogenesis of obesity is complex and
33	includes regulation of calorie utilization, appetite, and physical activity, as well as health care
34	availability, socioeconomic status, and underlying genetic and environmental factors (4,5).
35	The heritability of BMI has been widely reported. For instance, in twin studies, the
36	BMI heritability ranged from 30% to 90% (6-8), whereas in genome-wide association studies
37	(GWASs) it was estimated to be 20–30% (9–11), and only \sim 3% has been elucidated based on
38	genome wide significant loci (9,10). Although GWASs using BMI as an outcome have
39	identified over 100 associated loci (9-14), it remains unclear whether they all contribute to
40	the development of obesity via the same pathway. Indeed, the association of these genetic
41	variants with obesity may be explained by a polygenic model in which the effects of each
42	variant are weak yet contribute to the onset of obesity (15). Hence, if the genetic architecture
43	of obesity can be explained by a polygenic model, we would expect that larger sample sizes
44	correspond to more identified signals, whereas as fewer signals would be associated with
45	smaller sample sizes (Supplementary Figure 1). Meanwhile, within a genetically
46	heterogeneous population of obesity, if few variants exhibit a relatively strong influence
47	leading to obesity in a portion of the subtypes included therein, then dividing the population
48	with obesity into homogeneous groups could detect unique genes in each population, even
49	with a reduced sample size. However, to our knowledge, no GWASs have been conducted by
50	dividing persons with obesity into more homogeneous populations.

51	Traylor et al. demonstrated that attempts to categorize patients with a complex
52	disease into more homogeneous subgroups provided more power to elucidate hidden
53	heritability in a simulation study (16). Thus, clustering algorithms for machine learning could
54	reveal novel and more genetically homogeneous clusters. Accordingly, the purpose of this
55	study was to investigate the genetic architecture of obesity by dividing individuals with
56	obesity into clusters using various obesity-related factors and machine learning techniques
57	and performing GWAS on each cluster (cluster-based GWAS: cGWAS) (17,18).
58	
59	Methods
60	Population
61	This study was conducted according to the guidelines of the Declaration of Helsinki (19), and
62	the protocol was reviewed and approved by the Institutional Review Board of the Tohoku
63	Medical Megabank Organization. In the main study, we used data from cohort studies
64	conducted by the Tohoku Medical Megabank Project (TMM) Birth and Three- Generation
65	Cohort Study (BirThree Cohort Study) and the TMM Community-Based Cohort Study
66	(CommCohort Study) (20-22). The BirThree Cohort Study and CommCohort Study were
67	conducted in Miyagi and Iwate Prefectures, Japan. Details of the BirThree Cohort Study and
68	the CommCohort Study have been described elsewhere (21,22). In brief, the BirThree Cohort
69	Study is a birth and three-generation cohort study. Pregnant women were registered between
70	July 2013 and March 2017 (21). Additionally, pregnant women's partners (fetus' father),
71	pregnant women's parents and partner's parents (fetus' grandparents), as well as the fetus'
72	siblings and their relatives, were recruited (21). Among the BirThree Cohort Study
73	participants, fetus' mothers (n = 22,493), fetus' father (n = 8,823), and fetus' grandparents (n
74	= 8,058) were included in this study. The TMM CommCohort study is a community-based
75	prospective cohort study including men and women aged >20 years living in the Miyagi

Prefecture, northeastern Japan (22). The type 1 survey (n = 41,097) which performed in specific municipal health check-up sites, Type 2 survey (n = 13,855) which performed in assessment centers. (22).

79 Participants' data were excluded based on the following criteria: withdrew consent, failed to return the self-reported questionnaire, $BMI < 18.5 \text{ kg/m}^2$, missing information on the 80 81 food frequency questionnaire (FFQ), extreme energy intake (energy intake > mean ± 3 82 standard deviation [SD]), and duplicate participation in the both BirThree Cohort Study and 83 CommCohort Study Type-1 (the data of earlier date of participation were included). Data 84 from eligible participants of the BirThree Cohort Study (n = 23,479), CommCohort Study 85 Type-1 (n = 34,187), and CommCohort Study Type-2 (n = 12,485) were combined (n = 12,12,125) were combined (n = 12,125) were 86 70,151). In the sub-analysis, a similar analysis was performed using the UK Biobank (UKB) 87 data (23-25) to compare the results with those of the main study. Methods for analyzing the 88 UKB data are described in the supplementary information.

89

90 Genotyping, imputation, and quality control

91 Cohort participants were genotyped using the Affymetrix Axiom Japonica Array (v2) in 19 92 batches, with 50 plates set for each batch. Details pertaining to the genotyping performed in 93 TMM have been described previously (26). Following batch genotyping, samples with a call 94 rate < 0.95 or samples with unusually high IBD values compared to other samples, were 95 excluded. In addition, variants with Hardy-Weinberg equilibrium (HWE) *P*-values $< 1.00 \times$ 96 10^{-5} , minor allele frequency (MAF) < 0.01, or missing fraction > 0.01 were excluded from 97 each batch. A direct genotype dataset in PLINK BED format was obtained by merging the 98 genotype datasets for the 19 batches. A total of 21,541 participants with missing direct 99 genotype data were excluded. Principal component analysis (PCA) was performed using the -100 -pca approx option in PLINK 2.0 (27) on the direct genotype dataset and an additional 245

101	participants with > 4 SD for principal components 1 or 2 were excluded. Finally, a total of
102	48,365 participants (BirThree Cohort Study: $n = 11,674$, CommCohort Study Type-1: $n =$
103	27,745, CommCohort Study Type-2: $n = 8,946$) were included in the analysis (Figure 1).
104	Plot of participants ($n = 48,365$) according to principal component 1 and 2 by principal
105	component analysis was shown Supplementary Figure 2.
106	To prepare an imputed genotype dataset, pre-phasing was performed using
107	SHAPEIT2 (28), along with theduohmm option (29), which incorporates information on
108	the relatedness between individuals to increase phasing accuracy. The phased genotypes were
109	subsequently imputed with a cross-imputed panel of 3.5KJPNv2 (30) and 1KGP3 (31) using
110	IMPUTE4 (25). To create the cross-imputation panel for 3.5KJPNv2 (30) and 1KGP3 (31),
111	the -merge_ref_panels option in IMPUTE2 was applied (32). Consequently, we obtained an
112	imputed genotype dataset in the Oxford BGEN format
113	(https://www.well.ox.ac.uk/gav/qctool/). For genotype imputation data, those with minor
114	allele frequencies < 0.01 and imputation information scores < 0.8 were excluded. Finally,
115	9,868,333 SNPs were included in the GWASs.
116	
117	Variables
118	The following variables related to obesity were collected from questionnaires responded by
119	the participants at baseline for each cohort and used for clustering: age, nutrient intake
120	calculated from the FFQ based on frequency of food intake over the past year (energy,
121	protein, fat, carbohydrate, sodium, potassium, calcium, magnesium, phosphorus, iron, zinc,
122	copper, manganese, retinol equivalents, vitamin D, vitamin K, vitamin B1, vitamin B2, niacin,
123	vitamin B6, vitamin B12, folate, pantothenic acid, vitamin C, cholesterol, dietary fiber,
124	lycopene, α -carotene, β -carotene, and β -cryptoxanthin), frequency of leisure time physical

- 125 activity (slow walking, fast walking, moderate exercise, strenuous exercise; the choices

126	included: no activity, $<$ once per month, 1–3 times per month, 1–2 times per week, 3–4 times
127	per week, almost every day), time typically spent in physical activity per day (strenuous work,
128	walk, standing, sitting) according to predetermined options (no time, min < 30, $30 \le min < 60$,
129	$1 \le h < 3, \ 3 \le h < 5, \ 5 \le h < 7, \ 7 \le h < 9, \ 9 \le h < 11, \ h \ge 11), \ sleep \ duration \ (< 5 \ h, \ 5 \le h < 6, \ 6)$
130	\leq h < 7, 7 \leq h < 8, 8 \leq h < 9, h \geq 9), difference between weight at age 20 and current weight,
131	smoking (smoked > 100 cigarettes since birth; yes or no), alcohol consumption (> 1 drink per
132	month, quit, rarely, unable to drink), psychological distress over the past month (total K6
133	score [Japanese version]) (33,34), and birth weight (unknown, $1500 \le g < 2000$, $2000 \le$
134	2500, $2500 \le g < 3000$, $3000 \le g < 3500$, $3500 \le g < 4000$, $g \ge 4000$). In addition, cohort type
135	(BirThree Cohort Study, CommCohort study Type-1 and CommCohort study Type-2) was
136	added to the variables for the clustering.
137	The missing variables used for clustering were imputed using the k-nearest neighbor
138	(KNN) algorithm (35). KNN selects k samples close to the missing values in the feature
139	space and imputes the median of the k samples in the case of continuous variables, or the

140 most frequent category among the k samples in the case of categorical variables. KNN was

implemented using the R package VIM (36). Based on previous reports (35,37), we set k to

142 219 as an odd number close to the square root of 48,365 participants.

143

144 Body mass index

145 BMI was computed by dividing weight (kg) by the squared height (m²) using self-reported

146 height and weight on a questionnaire responded by the participants at baseline for each cohort.

147 A BMI > 25 kg/m² was defined as obese based on the Western Pacific Region of the World

148 Health Organization criteria for Asians (38).

149

150 Cluster analysis

151	The k-prototype is a clustering algorithm that combines k-means and k-modes and enables
152	clustering using continuous and categorical variables (39). The k-prototype was implemented
153	using the R package clustMixType (40). The number of clusters was set to 5. Continuous
154	variables were standardized by subtracting the mean of each variable and dividing it by the
155	SD before clustering.

156

157 Genome-wide association study

158 The GWASs with BMI as a continuous variable were conducted in 2 steps. Step-1: GWAS

159 was performed on all 48,365 participants. Step-2: 13,067 of the 48,365 participants were

160 clustered using the k-prototype to 5 clusters. Thereafter, participants in each of the 5 obesity

161 clusters and those with a BMI $< 25 \text{ kg/m}^2$ were combined, and the GWASs were performed

162 for each of the 5 clusters (Supplementary Figure 3). To identify associations between

autosomal SNPs and BMI, fastGWA with the GCTA software were employed (41).

164 FastGWA is a linear mixed model using a sparse genetic relationship matrix (GRM) that is

reportedly robust for population stratification and familial relationships (42). The top 20

166 principal components calculated from the PCA of the direct genotyping dataset, sex, age, and

167 cohort type (BirThree Cohort Study, CommCohort study type-1 and CommCohort study

type-2) were included as covariates. We set the Bonferroni genome-wide significance line at

169 $P < 8.33 \times 10^{-9}$ (5.0 × 10⁻⁸/6) as six GWASs were performed for Step-1 and Step-2. The

detected SNPs were annotated using the ANNOVAR (43). Manhattan plots and quantile-

171 quantile plots (Q-Q plots) were generated using R (version 4.1.0).

172

173 Results

174 Clustering

175	Following assignment of the 13,067 participants with obesity into 5 clusters, Cluster 1
176	contained 628 participants, Cluster 2 had 3,073, Cluster 3 had 4,111, Cluster 4 had 2,468, and
177	Cluster 5 contained 2,787. Table 1 shows the characteristics of obese participants (BMI \ge 25
178	kg/m^2) in each cluster. The variables were characterized by mean and SD for continuous
179	variables and by number and percentage for categorical variables. The participants in Cluster
180	1 had the highest energy and nutrient intakes, as well as a higher frequency of leisure-time
181	exercise. Cluster 2 was characterized by a higher proportion of women, older age, and the
182	highest percentage of nonsmokers. Cluster 3 participants had the lowest energy and nutrient
183	intake and a high proportion who did not exercise during leisure time nor perform their usual
184	physical activities (strenuous work, walking, and standing). Cluster 4 had the second-highest
185	energy and nutrient intake. Cluster 5 was characterized by the largest proportion of men,
186	lowest age, longest time spent standing or sitting, highest number of smokers, highest
187	proportion of alcohol drinkers, and highest scores for psychological distress.

188

189 Gene interpretation

- 190 We observed several genes that satisfied the $P < 8.33 \times 10^{-9}$ threshold in Step-1 (Figure 2 and
- 191 Supplementary Table 1). Most genes for which associations were detected in Step-1 are
- reportedly associated with obesity. More specifically, *LINC01741* (44–46) (Chr 1),
- 193 *CRYZL2P-SEC16B* (45,47) (Chr 1), *SEC16B* (46,47) (Chr 1), *TMEM18* (48,49) (Chr 2),
- 194 BDNF (45,47) (Chr 11), LINC00678 (50,51) (Chr 11), BDNF-AS (45,47) (Chr 11), FTO
- 195 (9,10,45,52) (Chr 16), MC4R (53,54) (Chr 18), GIPR (13) (Chr 19), and FBXO46 (50) (Chr
- 196 19) were previously associated with BMI. Meanwhile, *KIF18A* (Chr 11) was previously
- associated with visceral fat (55), *PMAIP1* (Chr 18) with serum IgE measurement (56) and
- 198 monocyte count (57,58), *RSPH6A* (Chr 19) with high and low density lipoprotein cholesterol

199	levels (59), SYMPK (Chr 19) with Type 2 diabetes mellitus (60) and total cholesterol levels
200	(50), and FOXA3 (Chr 19) with waist-to-hip ratio adjusted for BMI (52).
201	From the GWAS results in Step-2, several variants detected in Step-1 were observed
202	in separate clusters (Figure 3, Supplementary Table 2). Genome-wide associations were not
203	detected in Cluster 1. In Cluster 2, the loci that satisfied this threshold were identified as
204	LINC01741, CRYZL2P-SEC16B (Chr 1; intergenic), CRYZL2P-SEC16B, and SEC16B (Chr
205	1). Meanwhile, in Cluster 3, the FTO (chromosome 16), PMAIP1, and MC4R (chromosome
206	18; intergenic) loci were identified. For Cluster 4, BDNF (Chr 11), BDNF-AS (Chr 11),
207	BDNF-AS, LINC00678 (Chr 11), and BDNF, KIF18A (Chr 11) loci were identified.
208	Additionally, in Cluster 5, BDNF-AS, LINC00678 (Chr 11), LINC00678 (Chr 11), BDNF-AS
209	(Chr 11), BDNF (Chr 11), and BDNF, KIF18A (Chr 11) loci were identified (Figure 3).
210	Quantile-quantile plots corresponding to the GWAS results of the main study are shown in
211	Supplementary Figure 4.
212	In the sub-analysis, the UKB data was applied for comparison with the main study
213	results. In Step-1, we confirmed the association between representative obesity-related genes
214	and BMI (Supplementary Table 3 and Supplementary Figure 5). In Step-2, the clustering
215	results for the 32,779 obese participants revealed that revealed that Clusters 1-5 comprised
216	5,874, 6,497, 6,919, 6,733, and 6,756 participants, respectively. The characteristics of each
217	cluster are shown in Supplementary Table 4. In the GWAS results for Step-2, several variants
218	detected in Step-1 were found in separate clusters, similar to the TMM cohort analysis
219	(Supplementary Table 5 and Supplementary Figure 6).
220	
221	Discussion
222	Herein, we conducted a GWAS of all participants for BMI in Step-1. In Step-2, obese

participants (BMI \ge 25 kg/m²) were divided into 5 clusters based on obesity-related-factors,

224	and GWAS was performed for each of the 5 clusters. Consequently, several genes identified
225	in previous studies were confirmed in Step-1. Of the 18 genes detected in Step-1, LINC01741,
226	CRYZL2P-SEC16B, and SEC16B were significantly associated with Cluster 2, FTO, PMAIP1,
227	and MC4R to Cluster 3, and BDNF, BDNF-AS, BDNF-AS, LINC00678, and KIF18A to
228	Clusters 4 and 5. A similar phenomenon was observed in the sub-analysis using UKB data, in
229	which unique obesity-related genes were detected in each cluster.
230	It is important to consider how the cluster characteristics relate to the variants
231	identified in each cluster. Indeed, the GWAS results in Step-2 may be partially explained by
232	cluster characteristics. In cluster 1, significant associations were not detected, which might be
233	due to the low number of participants with a $BMI > 25.0 \text{ kg/m}^2$ as this cluster contained the
234	fewest obese participants. Hence, the detection power would have been insufficient.
235	FTO, PMAIP1, and MC4R (intergenic) variants were associated with BMI in Cluster
236	3. Variants in the FTO region regulate IRX3 and IRX5 expression (61), which promotes fat
237	accumulation and cause obesity. Meanwhile, melanocortin-4-receptors (MC4R) transcribed
238	by the MR4C gene regulate food intake and energy expenditure (62,63). Moreover, MC4R in
239	the paraventricular hypothalamus or amygdala controls food intake, while its expression
240	elsewhere is responsible for energy expenditure (62). Therefore, the genetic variants in FTO
241	and MC4R, which have been attributed to increased body fat accumulation and reduced
242	energy expenditure, may partially account for the obesity of individuals in Cluster 3 despite a
243	low energy intake.
244	In Cluster 4 and Cluster 5, BDNF and BDNF-AS variants were identified. Obese
245	participants in Cluster 4 had the second highest energy and nutrient intake, while those in
246	Cluster 5 had the highest mean score for psychological distress (K6 total score). Brain
247	derived neurotrophic factor (BDNF), which is transcribed by the BDNF gene, promotes the
248	development and growth of nerve cells and reportedly has anti-obesity effects (64,65).

249 Furthermore, transcription of the *BDNF-AS* (antisense RNA) gene is responsible for

250 regulating *BDNF* expression (66). Thus, altering BDNF regulation might affect the central

251 nervous system and alter eating behaviors and psychiatric conditions, as seen in this cluster.

252 In Cluster 2, SEC16B variants were detected; the obese participants in this cluster 253 had the highest proportion of women, increased age, and nonsmokers. Variants of SEC16B 254may be associated with obesity via regulation of dietary lipid absorption and appetite (67,68). 255 However, to our knowledge, no previous data has made direct connections between the 256characteristics of Cluster 2 participants and SEC16B variants. On the other hand, it should be 257 noted that the characteristics of clusters are not always recognizable to humans. That is, given 258 that clustering algorithms extract latent features by combining numerous variables, the 259 resulting clusters, although more homogeneous, are not necessarily comprehensible. Thus, it 260 will be necessary to define these obscure clusters identified by clustering algorithms.

261 This study has several strengths. First, the GWAS results had high validity. That is, 262 most genes detected in this study were previously reported to be associated with BMI. 263 Therefore, the GWAS data was considered appropriate. Second, the TMM and UKB cohorts 264 had various obesity-related factors. Using these 2 cohorts, it was possible to cluster the obese 265 population into more homogeneous groups using a rich set of obesity-related factors. Third, 266 the sub-analysis replicated the phenomenon, in which unique obesity-related genes were 267 detected in each cluster. This supports the hypothesis that obesity is an aggregation of 268 heterogeneous subgroups. The findings of this study suggest possibility that by dividing 269 obesity into homogeneous populations, fewer genetic variants could explain obesity in each 270 subgroup. Although many issues remain to be addressed to elucidate the full genetic 271 architecture of obesity, the current study provides important insights with the potential to 272 inform the development of personalized treatment or nutritional support for obesity. More 273 specifically, once clusters are identified, a classifier can be created using the cluster numbers

as training data, which can then be applied to classify obesity into subgroups and verify the
effectiveness of obesity treatment according to the subgroups.

276

277 Limitations

278 This study has certain limitations. First, it is unclear whether the selection of 279 variables, algorithm, or number of clusters was optimal. In this study, many factors related to 280 obesity were selected, however, the existence of unknown obesity-related factors cannot be 281 ruled out. In addition, the number of clusters in this study was arbitrarily set to 5. Therefore, 282 it is needed to explore them in the future. Second, obesity was assessed at a temporal point; 283 therefore, the possibility of misclassification may have occurred. Even those who were not 284 obese at the time of measurement had the potential to become obese with age. Third, the BMI 285 was calculated using height and weight from self-reported questionnaires in the main study. 286 Previous studies have shown no substantial differences between BMI calculated from self-287 reported height and weight and that calculated from measured height and weight, indicating 288 that self-reported weight and height are useful (69). Therefore, it is unlikely that the use of 289 self-reported height and weight data significantly distorted the results. Fourth, we could not 290 assess the heritability of each cluster due to the small sample size.

291

292 Conclusion

Our data suggest that a decreased sample size with increased homogeneity may reveal
 insights into the genetic architecture of obesity.

295

296 Acknowledgments

297 The authors thank the participants of the Tohoku Medical Megabank Project Birth and Three-

298 Generation Cohort Study, Community-Based Cohort Study, and UK Biobank. The authors

299	also thank the staff members of the Tohoku Medical Megabank Organization						
300	(https://www.megabank.tohoku.ac.jp/english/a210901/) and UK Biobank.						
301							
302	Author Contributions						
303	IT, HO, FU, TO, and SK designed research; IT conducted research; IT analyzed data; and IT						
304	HO, and SK wrote the paper. SK had primary responsibility for final content. All authors read						
305	and approved the final manuscript.						
306							
307	Data Sharing						
308	For the TMM biobank, data are available from the authors upon reasonable request and with						
309	the permission of the TMM biobank. All inquiries about access to the data should be sent to						

- the TMM biobank (dist@megabank.tohoku.ac.jp). For the UKB, the data will be available to 310
- 311 the public by requesting it from UK Biobank.

References

- Haslam DW, James WPT. Obesity. *Lancet.* 2005;366:1197–209. doi:10.1016/S0140-6736(05)67483-1
- Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. *Lancet*. 2005;365:1415– 28. doi:10.1016/S0140-6736(05)66378-7
- Ng, M, Fleming T, Robinson M, Thomson B, Graetz N, Margono EC, *et al.* Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet.* 2014;384:766–81. doi:10.1016/S0140-6736(14)60460-8
- Lin X, Li H. Obesity: Epidemiology, pathophysiology, and therapeutics. *Front Endocrinol (Lausanne)*. 2021;12:706978. doi:10.3389/fendo.2021.706978
- Lyon HN, Hirschhorn JN. Genetics of common forms of obesity: a brief overview. Am J Clin Nutr. 2015;82:215S–7S. doi:10.1093/ajcn/82.1.215S
- Feng R. How much do we know about the heritability of BMI?. *Am J Clin Nutr*. 2016;104:243–4. doi:10.3945/ajcn.116.139451
- Elks CE, den Hoed M, Zhao JH, Sharp SJ, Wareham NJ, Loos RJF, *et al.* Variability in the heritability of body mass index: a systematic review and meta-regression. *Front Endocrinol (Lausanne).* 2012;3:29. doi:10.3389/fendo.2012.00029
- Min J, Chiu DT, Wang Y. Variation in the heritability of body mass index based on diverse twin studies: a systematic review. *Obes Rev* 2013;14:871–82. doi:10.1111/obr.12065
- Akiyama M, Okada Y, Kanai M, Takahashi A, Momozawa Y, Ikeda M, *et al.* Genomewide association study identifies 112 new loci for body mass index in the Japanese population. *Nat Genet.* 2017;49:1458–6. doi:10.1038/ng.3951

- Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, *et al.* Genetic studies of body mass index yield new insights for obesity biology. *Nature* 2015;518:197–206. doi:10.1038/nature14177.
- 11. Yang J, Bakshi A, Zhu Z, Hemani G, Vinkhuyzen AE, Lee SH, *et al.* Genetic variance estimation with imputed variants finds negligible missing heritability for human height and body mass index. *Nat Genet.* 2015;47:1114–20. doi:10.1038/ng.3390
- Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, *et al.* Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nat Genet.* 2010;42:937–48. doi:10.1038/ng.686
- Wen W, Zheng W, Okada Y, Takeuchi F, Tabara Y, Hwang J-Y, *et al.* Meta-analysis of genome-wide association studies in East Asian ancestry populations identifies four new loci for body mass index. *Hum Mol Genet.* 2014;23:5492–504. doi:10.1093/hmg/ddu248
- Scuteri A, Sanna S, Chen W-M, Uda M, Albai G, Strait J, *et al.* Genome-wide association scan shows genetic variants in the FTO gene are associated with obesityrelated traits. *PLoS Genet.* 2007;3:e115. doi:10.1371/journal.pgen.0030115.
- Khera AV, Chaffin M, Wade KH, Zahid S, Brancale J, *et al.* Polygenic prediction of weight and obesity trajectories from birth to adulthood. *Cell.* 2019;177:587–96. doi:10.1016/j.cell.2019.03.028
- Traylor M, Markus H, Lewis CM. Homogeneous case subgroups increase power in genetic association studies. *Eur J Hum Genet*. 2015;23:863. doi:10.1038/ejhg.2014.194
- Ueno F, Onuma T, Takahashi I, Ohseto H, Narita A, Obara T, *et al.* Deep embedded clustering by relevant scales and genome-wide association study in autism. *bioRxiv*. 2022. doi:10.1101/2022.07.25.500917.

- Narita A, Nagai M, Mizuno S, Ogishima S, Tamiya G, Ueki M, *et al.* Clustering by phenotype and genome-wide association study in autism. *Transl Psychiatry*. 2020;10:290. doi:10.1038/s41398-020-00951-x
- World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA* 2013;310:2191–4. doi:10.1001/jama.2013.281053.
- Kuriyama S, Yaegashi N, Nagami F, Arai T, Kawaguchi Y, Osumi N, *et al.* The Tohoku Medical Megabank Project: Design and mission. *J Epidemiol.* 2016;26:493– 511. doi:10.2188/jea.JE20150268
- Kuriyama S, Metoki H, Kikuya M, Obara T, Ishikuro M, Yamanaka C, *et al.* Cohort Profile: Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study (TMM BirThree Cohort Study): rationale, progress and perspective. *Int J Epidemiol.* 2020;49:18–9. doi:10.1093/ije/dyz169
- Hozawa A, Tanno K, Nakaya N, Nakamura T, Tsuchiya N, Hirata T, *et al.* Study Profile of the Tohoku Medical Megabank Community Based Cohort Study. J *Epidemiol.* 2021;31:JE20190271. doi:10.2188/jea.JE20190271
- 23. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med.* 2015;12:e1001779. doi:10.1371/journal.pmed.1001779
- 24. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, *et al.* Genome-wide genetic data on ~500,000 UK Biobank participants. *bioRxiv*. 2017. doi:10.1101/166298.
- Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* 2018;562:203–9. doi:10.1038/s41586-018-0579-z

- 26. Yamada M, Motoike IN, Kojima K, Fuse N, Hozawa A, Kuriyama S, et al. Genetic loci for lung function in Japanese adults with adjustment for exhaled nitric oxide levels as airway inflammation indicator. *Commun Biol.* 2021;15:1288. doi:10.1038/s42003-021-02813-8
- Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: Rising to the challenge of larger and richer datasets. *Gigascience*. 2015;4:7. doi:10.1186/s13742-015-0047-8
- 28. Delaneau O, Zagury JF, Marchini J. Improved whole-chromosome phasing for disease and population genetic studies. *Nat Methods*. 2013;10:5–6. doi:10.1038/nmeth.2307.
- O'Connell J, Gurdasani D, Delaneau O, Pirastu N, Ulivi S, Cocca M, et al. A general approach for haplotype phasing across the full spectrum of relatedness. *PLoS Genet*. 2014;10:e1004234. doi:10.1371/journal.pgen.1004234.
- 30. Tadaka S, Katsuoka F, Ueki M, Kojima K, Makino S, Saito S, et al. 3.5KJPNv2: an allele frequency panel of 3552 Japanese individuals including the X chromosome. *Hum Genome Var.* 2019;6:28. doi:10.1038/s41439-019-0059-5
- The 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature*. 2015;526:68–74. doi:10.1038/nature15393
- Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet*. 2009;5:e1000529. doi:10.1371/journal.pgen.1000529
- Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SLT, *et al.* Short screening scales to monitor population prevalences and trends in non-specific psychological distress. *Psychol Med.* 2002;32:959–76. doi:10.1017/s0033291702006074

- 34. Furukawa TA, Kawakami N, Saitoh M, Ono Y, Nakane Y, Nakamura Y, et al. The performance of the Japanese version of the K6 and K10 in the World Mental Health Survey Japan. Int J Methods Psychiatr Res. 2008;17:152–8. doi:10.1002/mpr.257
- Zhang, Z. Introduction to machine learning: k-nearest neighbors. *Ann Transl Med.* 2016;4:2188. doi:10.21037/atm.2016.03.37.
- 36. Templ M, Kowarik A, Alfons A, de Cillia G, Prantner B, Rannetbauer W. Visualization and imputation of missing values. 2022. Available from: https://cran.rproject.org/web/packages/VIM/VIM.pdf
- 37. Lantz B. Machine learning with R: Expert techniques for predictive modeling to solve all your data analysis problems. 2nd ed. Birmingham-Mumbai: Packt Publishing, 2015.
- World Health Organization. Regional Office for the Western Pacific. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia, 2000. Available from: https://apps.who.int/iris/handle/10665/206936
- Huang Z. Extensions to the k-Means Algorithm for Clustering Large Data Sets with Categorical Values. *Data Min Knowl Discov*. 1998;2:283–304. doi:10.1023/A:1009769707641
- Package 'clustMixType' k-Prototypes Clustering for Mixed Variable-Type Data, 2021. Available from: https://cran.rproject.org/web/packages/clustMixType/clustMixType.pdf
- Wang Y, Ding X, Tan Z, Ning C, Xing K, Yang T, *et al.* Genome-wide association study of piglet uniformity and farrowing interval. *Front Genet.* 2017;8:194. doi:10.3389/fgene.2017.00194
- Jiang L, Zheng Z, Fang H, Yang J. A generalized linear mixed model association tool for biobank-scale data. *Nat Genet*. 2021;53:1616–21. doi:10.1038/s41588-021-00954-4

- Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* 2010;38:e164 doi:10.1093/nar/gkq603
- 44. Ng MCY, Graff M, Lu Y, Justice AE, Mudgal P, Liu C-T, *et al.* Discovery and finemapping of adiposity loci using high density imputation of genome-wide association studies in individuals of African ancestry: African Ancestry Anthropometry Genetics Consortium. *PLoS Genet.* 2017;13:e1006719. doi:10.1371/journal.pgen.1006719
- Wojcik GL, Graff M, Nishimura KK, Tao R, Haessler J, Gignoux CR, *et al.* Genetic analyses of diverse populations improves discovery for complex traits. *Nature* 2019;570:514–8. doi:10.1038/s41586-019-1310-4
- 46. Monda KL, Chen GK, Taylor KC, Palmer C, Edwards TL, Lange LA, *et al.* A metaanalysis identifies new loci associated with body mass index in individuals of African ancestry. *Nat Genet.* 2013;45:690–6. doi:10.1038/ng.2608
- 47. Thorleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P, Helgadottier A, *et al.* Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. *Nat Genet.* 2008;41:18–24. doi:10.1038/ng.274
- Pei YF, Zhang L, Liu Y, Li J, Shen H, Liu Y-Z, *et al.* Meta-analysis of genome-wide association data identifies novel susceptibility loci for obesity. *Hum Mol Genet*. 2014;23:820–30. doi:10.1093/hmg/ddt464
- 49. Willer CJ, Speliotes EK, Loos RJF, Li S, Lindgren CM, Heid IM, *et al.* Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. *Nat Genet.* 2008;41:25–34. doi:10.1038/ng.287

- Zhu Z, Guo Y, Shi H, Liu C-L, Panganiban RA, Chung W, *et al.* Shared genetic and experimental links between obesity-related traits and asthma subtypes in UK Biobank. *J Allergy Clin Immunol.* 2020;145:537–49. doi:10.1016/j.jaci.2019.09.035
- Tachmazidou I, Süveges D, Min JL, Ritchie GRS, Steinberg J, Walter K, *et al.* Wholegenome sequencing coupled to imputation discovers genetic signals for anthropometric traits. *Am J Hum Genet.* 2017;100:865–84. doi:10.1016/j.ajhg.2017.04.014
- Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, *et al.* A cross-population atlas of genetic associations for 220 human phenotypes. *Nat Genet*. 2021;53:1415–24. doi:10.1038/s41588-021-00931-x.
- Barton AR, Sherman MA, Mukamel RE, Loh PR. Whole-exome imputation within UK Biobank powers rare coding variant association and fine-mapping analyses. *Nat Genet*. 2021;53:1260–9. doi:10.1038/s41588-021-00892-1
- Akbari P, Gilani A, Sosina O, Kosmicki JA, Khrimian L, Fang Y-Y, *et al.* Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity. *Science* 2021;373:eabf8683. doi:10.1126/science.abf8683.
- Shin J, Syme C, Wang D, Richer L, Pike GB, Gaudet D, et al. Novel genetic locus of visceral fat and systemic inflammation. *J Clin Endocrinol Metab.* 2019;104:3735–42. doi:10.1210/jc.2018-02656
- 56. Akenroye AT, Brunetti T, Romero K, Daya M, Kanchan K, Shankar G, et al. Genomewide association study of asthma, total IgE, and lung function in a cohort of Peruvian children. *J Allergy Clin Immunol*. 2021;148:1493–504. doi:10.1016/j.jaci.2021.02.035.
- Chen MH, Raffield LM, Mousas A, Sakaue S, Huffman JE, Moscati A, et al. Transethnic and ancestry-specific blood-cell genetics in 746,667 individuals from 5 global populations. *Cell*. 2020;182:1198–213. doi:10.1016/j.cell.2020.06.045

- Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, et al. The polygenic and monogenic basis of blood traits and diseases. *Cell*. 2020;182:1214–31. doi:10.1016/j.cell.2020.08.008
- 59. Sinnott-Armstrong N, Tanigawa Y, Amar D, Mars N, Benner C, Aguirre M, et al. Genetics of 35 blood and urine biomarkers in the UK Biobank. *Nat Genet*. 2021;53:185–94. doi:10.1038/s41588-020-00757-z
- 60. Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, et al. Finemapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. *Nat Genet*. 2018;50:1505–13 doi:10.1038/s41588-018-0241-6
- Claussnitzer M, Dankel SN, Kim K-H, Quon G, Meuleman W, Haugen C, *et al.* FTO obesity variant circuitry and adipocyte browning in humans. *N Engl J Med.* 2015;373:895–907. doi:10.1056/NEJMoa1502214
- Balthasar N, Dalgaard LT, Lee CE, Yu J, Funahashi H, Williams T, *et al.* Divergence of melanocortin pathways in the control of food intake and energy expenditure. *Cell*. 2005;123:493–505. doi:10.1016/j.cell.2005.08.035
- Krashes MJ, Lowell BB, Garfield AS. Melanocortin-4 receptor–regulated energy homeostasis. *Nat Neurosci*. 2016;19:206–19. doi:10.1038/nn.4202
- Noble EE, Billington CJ, Kotz CM, Wang CF. The lighter side of BDNF. *Am J Physiol Regul Integr Comp Physiol*. 2011;300:R1053. doi:10.1152/ajpregu.00776.2010
- Pandit M, Behl T, Sachdeva M, Arora S. Role of brain derived neurotropic factor in obesity. *Obes Med.* 2020;17:100189. Doi:10.1016/j.obmed.2020.100189
- Ghafouri-Fard S, Khoshbakht T, Taheri M, Ghanbari M. A concise review on the role of BDNF-AS in human disorders. *Biomed Pharmacother*. 2021;142:112051. doi:10.1016/j.biopha.2021.112051

- 67. Shi R, Lu W, Tian Y, Wang B, Ave L. Intestinal SEC16B modulates obesity by controlling dietary lipid absorption. *bioRxiv*. 2021. doi:10.1101/2021.12.07.471468.
- Hotta K, Nakamura M, Nakamura T, Matsuo T, Nakata Y, Kamohara S, *et al.* Association between obesity and polymorphisms in SEC16B, TMEM18, GNPDA2,
 BDNF, FAIM2 and MC4R in a Japanese population. *J Hum Genet.* 2009;54:727–31.
 doi:10.1038/jhg.2009.106.
- Haakstad LAH, Stensrud T, Gjestvang C. Does self-perception equal the truth when judging own body weight and height? *Int J Environ Res Public Health*. 2021;18:8502. doi:10.3390/ijerph18168502.

Number of posticipants with the iter in such 1 of	428	2072	4111	2468	2797
number of participants with obesity in each cluster	628	30/3	4111	2408	2/8/
TMM BirThree Cohort Study	69 (11.0)	311 (10.1)	1157 (28.1)	347 (14.1)	911 (32.7)
TMM CommCohort StudyType-1	461 (73.4)	2185 (71.1)	2308 (56.1)	1671 (67.7)	1459 (52.4)
TMM CommCohort StudyType-2	98 (15.6)	577 (18.8)	646 (15.7)	450 (18.2)	417 (15.0)
Body mass index (kg/m ⁻), mean (SD) Say (Female) n (%)	27.89 (2.86) 429 (68 3)	27.52 (2.86)	27.89 (3.01)	27.75 (3.40) 1441 (58.4)	27.97 (3.15)
Age, mean (SD)	63.19 (10.49)	63.91 (8.82)	53.05 (14.97)	61.78 (11.26)	50.13 (14.43)
Energy intake (kcal/day), mean (SD)	3698.48 (614.37)	1762.55 (297.63)	1365.83 (383.23)	2724.54 (520.18)	2249.39 (398.18)
Protein intake (g/day), mean (SD)	165.21 (42.58)	64.05 (11.88)	42.76 (12.30)	107.01 (21.94)	78.60 (13.97)
Fat intake (g/day), mean (SD)	148.20(42.11)	54.36(14.77)	36.24 (14.24)	96.63(29.90)	72.43(21.84)
Carbohydrate intake (g/day), mean (SD)	405.20 (102.38)	238.40 (53.37)	185.68 (59.18)	326.16 (76.90)	273.02 (68.82)
Sodium intake (mg/day), mean (SD)	10076.84 (3514.42)	4152.44 (1175.43)	2463.53 (960.69)	6591.02 (1819.89)	4508.60 (1262.10)
Potassium intake (mg/day), mean (SD)	7160.45 (1605.83)	2800.74 (551.85)	1526.41 (486.92)	4439.55 (782.99)	2715.77 (544.54)
Calcium intake (mg/day), mean (SD)	1706.40 (956.58)	563.50 (200.86)	308.26 (156.96)	987.82 (489.58)	592.21 (296.28)
Phosphorus intake (mg/day), mean (SD)	2688.34 (742.22)	1025.36 (191.87)	667.55 (195.26)	1716.71 (393.09)	1222.02 (245.29)
Iron intake (mg/day), mean (SD)	20.44 (6.03)	8.73 (1.83)	5.16 (1.53)	13.11 (2.88)	8.65 (1.79)
Zinc intake (mg/day), mean (SD)	17.98 (4.16)	7.55 (1.31)	5.42 (1.50)	12.02 (2.47)	9.34 (1.78)
Copper intake (mg/day), mean (SD)	2.70 (0.85)	1.24 (0.24)	0.79 (0.22)	1.81 (0.38)	1.26 (0.24)
Manganese intake (mg/day), mean (SD)	6.83 (2.79)	4.13 (1.66)	2.42 (1.01)	5.19 (1.96)	3.37 (1.09)
Retinol intake (µg/day), mean (SD)	2120.19 (1639.68)	602.68 (332.58)	312.40 (229.58)	1105.44 (661.04)	666.65 (452.91)
Vitamin D intake (mg/day), mean (SD)	23.75 (26.41)	7.07 (4.35)	3.78 (2.98)	13.43 (8.96)	8.59 (5.38)
Vitamin K intake (µg/day), mean (SD)	944.42 (743.11)	313.91 (163.46)	154.52 (102.94)	486.57 (298.52)	271.11 (127.74)
Vitamin B1 intake (mg/day), mean (SD) Vitamin B2 intake (mg/day), mean (SD)	2.24 (0.51)	0.92 (0.21)	0.57 (0.19)	2 30 (0.54)	1.03 (0.23)
Niacin intake (mg/day), mean (SD)	40.43 (15.25)	17.13 (4.22)	11.57 (4.19)	28.18 (8.00)	21.27 (5.65)
Vitamin B6 intake (mg/day), mean (SD)	3.40 (0.85)	1.37 (0.26)	0.83 (0.26)	2.21 (0.40)	1.50 (0.31)
VitaminB12 intake (mg/day), mean (SD)	19.14 (12.10)	5.75 (2.88)	3.33 (2.13)	11.31 (5.82)	7.62 (3.67)
Folic acid intake (µg/day), mean (SD)	1001.59 (347.25)	402.90 (107.44)	194.46 (75.65)	599.17 (155.75)	331.59 (88.21)
Vitamin C intake (mg/day), mean (SD)	332.58 (178.51)	143.77 (58.10)	54.52 (32.39)	205.01 (93.32)	90.81 (39.33)
Cholesterol intake (mg/day), mean (SD)	735.15 (554.89)	229.51 (106.63)	160.33 (93.09)	429.94 (270.69)	342.50 (194.53)
Dietary fiber intake (g/day), mean (SD)	35.50 (15.50)	14.62 (4.11)	7.30 (2.98)	21.51 (6.67)	12.25 (3.80)
Lycopene intake ($\mu g/day$), mean (SD)	6666.82 (10005.23) 1658 00 (2005.73)	3094.68 (5244.45) 580 70 (718 90)	1252.77 (2849.40)	5061.35 (9101.55) 864.46 (1002.82)	2117.82 (3576.83)
B-carotene intake (µg/day), mean (SD)	9667.42 (8422.51)	3306.81 (2244.96)	1416.89 (1084.96)	5038.74 (3517.34)	2466.99 (1469.77)
β-Cryptoxanthin intake (µg/day), mean (SD)	2725.27 (3071.63)	1282.12 (1427.77)	382.64 (568.93)	1760.34 (2027.22)	592.89 (649.73)
quency of leisure time physical activity, Slow walking, n (%)					
No activity	164 (26.1)	989 (32.2)	1521 (37.0)	724 (29.3)	991 (35.6)
< Once per month	52 (8.3)	231 (7.5)	473 (11.5)	207 (8.4)	302 (10.8)
1–3 times per month	74 (11.8)	428 (13.9)	671 (16.3)	320 (13.0)	491 (17.6)
1–2 times per week	99 (15.8)	484 (15.8)	513 (12.5)	349 (14.1)	375 (13.5)
3-4 times per week	93 (14.8)	340 (11.1)	342 (8.3)	315 (12.8)	243 (8.7)
Annost every day	140 (23.2)	001 (19.6)	391 (14.4)	555 (22.4)	365 (13.6)
No activity	329 (52.4)	1820 (59.2)	2794 (68.0)	1334 (54.1)	1790 (64.2)
< Once per month	68 (10.8)	206 (6.7)	374 (9.1)	204 (8.3)	276 (9.9)
1–3 times per month	47 (7.5)	273 (8.9)	281 (6.8)	238 (9.6)	233 (8.4)
1–2 times per week	63 (10.0)	260 (8.5)	241 (5.9)	254 (10.3)	191 (6.9)
3-4 times per week	53 (8.4)	227 (7.4)	168 (4.1)	191 (7.7)	143 (5.1)
Almost every day	68 (10.8)	287 (9.3)	253 (6.2)	247 (10.0)	154 (5.5)
equency of leisure time physical activity, Moderate exercise n (%)	100 (20 4)	0/2/21/21			120
No activity	189 (30.1)	963 (31.3)	516 (12.6)	744 (30.1)	1302 (46.7)
< Once per month	77 (12.3)	499 (16.2)	642 (15.6)	403 (16.3)	491 (17.6)
1-2 times per week	101 (16.1)	582 (18.9)	389 (9.5)	394 (16.0)	311 (11.2)
3-4 times per week	105 (16.7)	433 (14.1)	252 (6.1)	378 (15.3)	185 (6.6)
Almost every day	100 (15.9)	341 (11.1)	167 (4.1)	300 (12.2)	115 (4.1)
equency of leisure time physical activity, Strenuous exercise, n (%)					
No activity	515 (82.0)	2670 (86.9)	3515 (85.5)	1989 (80.6)	2262 (81.2)
< Once per month	34 (5.4)	74 (2.4)	175 (4.3)	119 (4.8)	158 (5.7)
1–3 times per month	18 (2.9)	91 (3.0)	140 (3.4)	133 (5.4)	163 (5.8)
1–2 times per week	31 (4.9)	148 (4.8)	170 (4.1)	123 (5.0)	127 (4.6)
3-4 times per week	25 (3.7)	75 (2.4)	89 (2.2)	87 (3.5)	58 (2.1) 19 (0.7)
Aimosi every day ne typically spent in physical activity per day. Strennous work. p. (%)		13 (0.3)	-22 (03)	17 (0.7)	17 (0.7)
No time	152 (24.2)	1117 (36.3)	1537 (37.4)	707 (28.6)	817 (29.3)
min < 30	133 (21.2)	655 (21.3)	991 (24.1)	502 (20.3)	696 (25.0)
$30 \le \min < 60$	86 (13.7)	407 (13.2)	498 (12.1)	347 (14.1)	399 (14.3)
$1 \leq h < 3$	115 (18.3)	477 (15.5)	529 (12.9)	438 (17.7)	422 (15.1)
$3 \leq h < 5$	78 (12.4)	233 (7.6)	284 (6.9)	242 (9.8)	217 (7.8)
$5 \le h < 7$	39 (6.2)	135 (4.4)	161 (3.9)	151 (6.1)	136 (4.9)
$7 \le h < 9$	20 (3.2)	40 (1.3)	92 (2.2)	55 (2.2)	77 (2.8)
9 ≤ h < 11	2 (0.3)	2 (0.1)	14 (0.3)	16 (0.6)	20 (0.7)
h≥ll me typically spent in physical activity per day, walk, p. (%)	3 (0.5)	7 (0.2)	5 (0.1)	10 (0.4)	3 (0.1)
c spready spent in physical activity per tray, waik, it (70)	14/2.0	20 (1 2)	89 (2 1)	44 (1 8)	44.0.0
No time	4.1.1.	.19 (1 1)	00.00		44
No time min < 30	88 (14.0)	412 (13.4)	841 (20.5)	340 (13.8)	545 (19.6)

$30 \leq \min < 60$	173 (27.5)	753 (24.5)	1137 (27.7)	642 (26.0)	966 (34.7)
$1 \le h < 3$	212 (33.8)	1331 (43.3)	1360 (33.1)	941 (38.1)	723 (25.9)
3≤h<5	66 (10.5)	318 (10.3)	367 (8.9)	278 (11.3)	269 (9.7)
$5 \le h < 7$	41 (6.5)	143 (4.7)	186 (4.5)	125 (5.1)	138 (5.0)
$7 \le h < 9$	21 (3.3)	48 (1.6)	91 (2.2)	61 (2.5)	67 (2.4)
$9 \le h < 11$	10 (1.6)	16 (0.5)	22 (0.5)	30 (1.2)	24 (0.9)
h ≥11	3 (0.5)	13 (0.4)	19 (0.5)	7 (0.3)	11 (0.4)
Time typically spent in physical activity per day, Standing, n (%)					
No time	10 (1.6)	39 (1.3)	96 (2.3)	35 (1.4)	41 (1.5)
min < 30	49 (7.8)	215 (7.0)	439 (10.7)	191 (7.7)	336 (12.1)
$30 \le \min < 60$	79 (12.6)	459 (14.9)	643 (15.6)	335 (13.6)	465 (16.7)
$1 \le h < 3$	222 (35.4)	1169 (38.0)	1398 (34.0)	902 (36.5)	842 (30.2)
$3 \le h < 5$	142 (22.6)	647 (21.1)	748 (18.2)	506 (20.5)	499 (17.9)
$5 \le h < 7$	75 (11.9)	326 (10.6)	450 (10.9)	300 (12.2)	314 (11.3)
$7 \le h < 9$	35 (5.6)	148 (4.8)	233 (5.7)	135 (5.5)	187 (6.7)
$9 \le h < 11$	8 (1.3)	51 (1.7)	73 (1.8)	45 (1.8)	64 (2.3)
h ≥11	8 (1.3)	19 (0.6)	31 (0.8)	19 (0.8)	39 (1.4)
Time typically spent in physical activity per day, Sitting, n (%)					
No time	10 (1.6)	34 (1.1)	48 (1.2)	29 (1.2)	31 (1.1)
min < 30	18 (2.9)	73 (2.4)	108 (2.6)	86 (3.5)	84 (3.0)
$30 \le \min < 60$	60 (9.6)	195 (6.3)	311 (7.6)	173 (7.0)	231 (8.3)
$1 \leq h < 3$	213 (33.9)	824 (26.8)	1070 (26.0)	682 (27.6)	761 (27.3)
$3 \le h < 5$	190 (30.3)	1159 (37.7)	1410 (34.3)	871 (35.3)	824 (29.6)
$5 \leq h < 7$	87 (13.9)	495 (16.1)	659 (16.0)	391 (15.8)	459 (16.5)
$7 \leq h < 9$	30 (4.8)	180 (5.9)	284 (6.9)	144 (5.8)	214 (7.7)
$9 \le h < 11$	11 (1.8)	60 (2.0)	139 (3.4)	51 (2.1)	99 (3.6)
h ≥11	9 (1.4)	53 (1.7)	82 (2.0)	41 (1.7)	84 (3.0)
Sleep duration, n (%)					
< 5 h	56 (8.9)	169 (5.5)	291 (7.1)	151 (6.1)	182 (6.5)
$5 \le h < 6$	158 (25.2)	1096 (35.7)	1156 (28.1)	656 (26.6)	677 (24.3)
$6 \leq h < 7$	213 (33.9)	984 (32.0)	1646 (40.0)	995 (40.3)	1258 (45.1)
$7 \le h < 8$	142 (22.6)	617 (20.1)	732 (17.8)	464 (18.8)	508 (18.2)
$8 \le h < 9$	46 (7.3)	179 (5.8)	238 (5.8)	168 (6.8)	148 (5.3)
$h \ge 9$	13 (2.1)	28 (0.9)	48 (1.2)	34 (1.4)	14 (0.5)
Difference between weight at age 20 and current weight, mean (SD)	10.86 (9.75)	10.48 (8.86)	11.31 (9.03)	11.28 (9.49)	11.99 (9.49)
Not smoked more than 100 cigarettes since birth, n (%)	446 (71.0)	2379 (77.4)	1961 (47.7)	1559 (63.2)	959 (34.4)
Alcohol drinking, n (%)					
>1 drink per month	277 (44.1)	1115 (36.3)	2274 (55.3)	1313 (53.2)	1918 (68.8)
Quit	18 (2.9)	79 (2.6)	169 (4.1)	63 (2.6)	113 (4.1)
Rarely	301 (47.9)	1688 (54.9)	1440 (35.0)	935 (37.9)	614 (22.0)
Unable to drink	32 (5.1)	191 (6.2)	228 (5.5)	157 (6.4)	142 (5.1)
Total score of K6, n (%)	4.74 (4.75)	3.81 (3.91)	4.61 (4.65)	4.36 (4.39)	5.12 (4.88)
Birth weight, n (%)					
Unknown	263 (41.9)	1559 (50.7)	1303 (31.7)	1021 (41.4)	493 (17.7)
$1500 \le g < 2000$	17 (2.7)	60 (2.0)	68 (1.7)	58 (2.4)	46 (1.7)
$2000 \le g < 2500$	57 (9.1)	223 (7.3)	300 (7.3)	186 (7.5)	188 (6.7)
$2500 \le g < 3000$	159 (25.3)	727 (23.7)	1065 (25.9)	625 (25.3)	731 (26.2)
$3000 \le g < 3500$	102 (16.2)	376 (12.2)	1057 (25.7)	451 (18.3)	1079 (38.7)
$3500 \le g < 4000$	26 (4.1)	108 (3.5)	273 (6.6)	110 (4.5)	203 (7.3)
g ≥ 4000	4 (0.6)	20 (0.7)	45 (1.1)	17 (0.7)	47 (1.7)

The characteristics of obese participants in each cluster.

The variables are characterized by the mean and standard deviation for continuous variables and by number and percentage for categorical variables.

In the case of continuous variables, the cluster with the higher mean is colored red, and the cluster with the lower mean is colored blue.

In the case of categorical variables, the clusters with the higher percentages are colored red, and those with the lower percentages are colored blue.

Figure Legends

Figure 1. Flow chart of exclusion criteria in this study.

The participants data from each cohort were excluded based on the following criteria.

Figure 2. Manhattan plot of Step-1.

A GWAS with BMI as a continuous variable was performed on 48,365 participants.

Figure 3. Manhattan plots of Step-2.

We clustered 13,067 of the 48,356, individuals with BMI \geq 25kg/m² using the k-prototype. Thereafter, participants with obesity in each of the 5 clusters and those with BMI< 25kg/m² were then combined and GWAS was performed according to the 5 clusters (cluster-based GWAS: cGWAS).

Supplementary Figure 1. Virtual Manhattan plots with different number of participants.

Supplementary Figure 2. Plot of participants according to principal component 1 and 2 by principal component analysis.

Supplementary Figure 3. Details of the cluster-based GWAS.

Supplementary Figure 4. quantile-quantile plots and lambda values in main study.

Supplementary Figure 5. Manhattan plots (a) and corresponding quantile-quantile plots (b) of Step-1 in sub-analysis.

Supplementary Figure 6. Manhattan plots (a) and corresponding quantile-quantile plots

(b) of Step-2 in sub-analysis.



Figure 1. Flow chart of exclusion criteria in this study.



Figure 2. Manhattan plot of Step-1.



Figure 3. Manhattan plots of Step-2.